News &amp; Updates

Neoadjuvant treatment with tiragolumab plus atezolizumab, with or without chemotherapy, is feasible in advanced resectable non-small cell lung cancer (NSCLC), having an acceptable safety profile and yielding major pathologic response (MPR) rates comparable to that observed with other perioperative immunotherapy plus chemotherapy regimens, according to the phase II SKYSCRAPER-05 trial.

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

Some patients with nonsmall-cell lung cancer (NSCLC) have somatic DNA methyltransferase 3A (DNMT3A) mutations, which are associated with a reduced DNMT3A expression and a favourable immunophenotype, reveals a study.

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

SGLT-2i lowers autoimmune rheumatic disease risk in T2D

The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, results in a reduced risk of autoimmune rheumatic disease among adults with type 2 diabetes (T2D), reports a recent study.

SGLT-2i lowers autoimmune rheumatic disease risk in T2D

04 Nov 2025

Which exercise works best for people with knee OA?

Aerobic exercise appears to be the best form of workout for people with knee osteoarthritis (OA), resulting in improved pain, function, gait performance, and quality of life (QoL), suggests a study.

Which exercise works best for people with knee OA?

Shift work a risk factor for kidney stones

A recent study suggests a positive association between shift work and risk of kidney stone events, with lifestyle factors partially mediating the association.

Shift work a risk factor for kidney stones

04 Nov 2025

Heart failure outcomes better with nonsteroidal vs steroidal MRAs

In the treatment of patients with heart failure, the use of nonsteroidal mineralocorticoid receptor antagonists (MRAs) such as finerenone appears to improve clinical outcomes compared with steroidal MRAs, as shown in a retrospective study.

Heart failure outcomes better with nonsteroidal vs steroidal MRAs

Semaglutide safe for dialysis patients in pooled analysis

Treatment with the GLP-1 receptor agonist semaglutide appears safe for patients initiating dialysis, as demonstrated in a pooled analysis presented at EASD 2025.

Semaglutide safe for dialysis patients in pooled analysis

Seizures common in congenital heart disease

Infants appear to have a more than fivefold greater odds of experiencing seizures in the presence of congenital heart disease (CHD), according to a study.

Seizures common in congenital heart disease

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

03 Nov 2025 by

In the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), the combination of cemiplimab plus chemotherapy continued to provide superior benefits compared with chemotherapy alone, according to 5-year data from the phase III EMPOWER-Lung part 2 trial.

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

Extended PLND tied to improved survival in bladder cancer

In patients with bladder cancer, extended pelvic lymph node dissection (PLND) is associated with favourable recurrence-free survival and 5-year recurrence rates, a study has shown.

Extended PLND tied to improved survival in bladder cancer